【9.29活动】BioSpark聊biotech news：2024年九月生物医药大事讨论

文章预览

各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的 生物医药领域大事件 。 本月热点 TOPICS 1 .    Oncology ： Summit/Akeso’s PD1 X VEGF bispecific antibody Ivonescimab showed PFS benefit over Keytruda in 1L NSCLC phase 3 study; Biotheus announced phase 2 data of their PD-L1 X VEGF bispecific antibody; Eli Lilly launched 750-patient phase 1 study for their pan-KRAS inhibitor ; Amgen’s PRMT5 inhibitor AMG193 showed preliminary clinical activity in MTAP-deleted solid tumors; Astellas provided phase 1 updates on KRAS G12D degrader ASP3082; BMS launched phase 3 study of anti-PD1 + anti-LAG3 combination therapy in 1L NSCLC; AstraZeneca / Daiichi's TROP2-directed ADC failed to improve overall survival in phase 3 trials of breast cancer and NSCLC; 2 .   Autoimmune Diseases: Boehringer Ingelheim's nerandomilast met the primary end point in the pivotal phase 3 FIBRONEER-IPF trial; UCB & Biogen announced positive topline phase 3 results of ………………………………